- Home
- EOLS vs CCCX Comparison
EOLS vs CCCX Comparison
Compare EOLS & CCCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- CCCX
- Stock Information
- Founded
- EOLS 2012
- CCCX 2024
- Country
- EOLS United States
- CCCX United States
- Employees
- EOLS N/A
- CCCX N/A
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- CCCX Blank Checks
- Sector
- EOLS Health Care
- CCCX Finance
- Exchange
- EOLS Nasdaq
- CCCX Nasdaq
- Market Cap
- EOLS 493.5M
- CCCX 527.0M
- IPO Year
- EOLS 2018
- CCCX 2025
- Fundamental
- Price
- EOLS $7.66
- CCCX $10.11
- Analyst Decision
- EOLS Strong Buy
- CCCX
- Analyst Count
- EOLS 5
- CCCX 0
- Target Price
- EOLS $21.25
- CCCX N/A
- AVG Volume (30 Days)
- EOLS 1.2M
- CCCX 11.6K
- Earning Date
- EOLS 11-05-2025
- CCCX 01-01-0001
- Dividend Yield
- EOLS N/A
- CCCX N/A
- EPS Growth
- EOLS N/A
- CCCX N/A
- EPS
- EOLS N/A
- CCCX 0.14
- Revenue
- EOLS $277,941,000.00
- CCCX N/A
- Revenue This Year
- EOLS $14.01
- CCCX N/A
- Revenue Next Year
- EOLS $29.46
- CCCX N/A
- P/E Ratio
- EOLS N/A
- CCCX $269.43
- Revenue Growth
- EOLS 17.15
- CCCX N/A
- 52 Week Low
- EOLS $5.71
- CCCX $10.22
- 52 Week High
- EOLS $17.82
- CCCX $10.50
- Technical
- Relative Strength Index (RSI)
- EOLS 50.21
- CCCX N/A
- Support Level
- EOLS $7.19
- CCCX N/A
- Resistance Level
- EOLS $7.67
- CCCX N/A
- Average True Range (ATR)
- EOLS 0.34
- CCCX 0.00
- MACD
- EOLS 0.13
- CCCX 0.00
- Stochastic Oscillator
- EOLS 79.29
- CCCX 0.00
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
About CCCX Churchill Capital Corp X Class A Ordinary Shares
Churchill Capital Corp X is a blank check company.